Jill Eichele-Guary

Clinical research has a secret ingredient, and it’s not in any lab. It’s the people. Their judgment. Their precision. Their ability to keep complexity under control. Technology helps. Processes guide. But the professionals behind the scenes? They’re the ones who make trials move, adapt, and succeed. And the ones who truly stand out? They blend scientific mastery with human intelligence. They see risks before they appear. They solve problems before they grow. They carry the field forward, one decision at a time. That’s the idea behind today’s infographic... A fresh take on what defines top-tier clinical research talent. At Interim Visits, we highlight the skills, mindsets, and systems that power stronger clinical research every day. Follow us for insights that help you grow in this field. #ClinicalResearch #InterimVisits #LifeSciences #ClinicalTrials #ResearchCareers #CRA #GCP #HealthcareInnovation

6

2 Comments

Clinical research teams don’t need more dashboards — they need clarity. Data Discern Bridges™ turns complex clinical and regulatory data into focused, decision-ready insights so teams can spend less time chasing details and more time advancing trials that help patients. From protocol-aligned data analysis to regulatory document strategy, our fractional support plugs into your existing workflows to strengthen data integrity and audit readiness.

4

Should the role of CIO stay the same over time? Jonathan Shough doesn't think so. In this episode of What’s New in Data, Parexel's CIO, Jonathan Shough shares how his team is reshaping the role of data and technology in clinical research—from powering scientific work to putting AI in the hands of every employee. Whether you're a project manager or an executive assistant, you're now part of the data conversation. 🎧 Listen to the full episode: https://lnkd.in/eCyM88iq

11

At Connect Communications, we support the development of real-world evidence studies that generate meaningful insights from clinical practice, helping stakeholders better understand treatment effectiveness, patient outcomes, and unmet needs across therapy areas. From study design and protocol development to scientific analysis and publication support, our team helps translate real-world data into impactful evidence. Get in touch to learn more. #RealWorldEvidence #HealthcareResearch #MedicalCommunications

14

Better data leads to better decisions. Yet in women’s health, the tools to capture meaningful outcomes are often outdated or misaligned. ICON is helping sponsors rethink COA selection and endpoint design to reflect the real experiences of women. Read the full blog: https://ow.ly/6Qch50WkWx7 #WomensHealth #ClinicalResearch #COA #PatientCentricity #ICONplc

29

1 Comment

Navigating the competitive landscape of Acute Lymphocytic Leukemia (ALL)? The key to a winning commercial strategy lies beyond the initial diagnosis. At Prognos Health, we understand that granular lab data—from immunophenotyping to MRD testing—is the real roadmap. It helps you anticipate market needs and identify the right patients at the right time. Learn how to unlock these insights in our blog post: https://bit.ly/4nkqPwS #PrognosHealth #ALL #Oncology #Pharma #CommercialExcellence #HealthcareData #PatientJourney

6

Impactful real-world evidence from the EMBER study: Type 2 (T2)-targeted biologic therapies improve outcomes across all patient clusters, including T2-low asthma, but more effective treatments are needed.   The EMBER study, “Response to biologics along a gradient of T2 involvement in patients with severe asthma: a data-driven biomarker clustering approach”, was recently published in The Journal of Allergy and Clinical Immunology: In Practice. It included 3,675 patients from 23 countries in the International Severe Asthma Registry (ISAR). Five biomarker clusters along a gradient of T2 involvement were identified using a data-driven approach. Biologic use (Anti-IgE, Anti-IL5/5R and Anti-IL4Rα) was associated with improved outcomes in all clusters but tended to be better at the higher end of the T2 spectrum. T2-targeted biologics have utility in the management of triple-biomarker-low asthma, though further research is needed to identify pathways specific to T2-low asthma that can be targeted by treatment. Read the full press release: https://lnkd.in/gj2gE-Ni Read the full article here: https://lnkd.in/gsUuVSGQ Learn more about ISAR at https://lnkd.in/eTCp_Dig. #SevereAsthma #Biologics #Biomarkers #ISAR #Research [Figure: Biomarker clusters of patients with severe asthma, identified using Gaussian finite mixture models]

5

🌍 Pfizer is transforming patient outcomes with the power of trusted data and AI. With Strategy One, thousands of field representatives across dozens of countries have real-time insights at their fingertips. This creates more meaningful conversations with healthcare providers and improves patient care on a global scale. This unified data ecosystem drives productivity, scalability, and smarter decision-making, therefore helping Pfizer enhance healthcare worldwide. 👉 Watch the full story: https://ow.ly/H6ih50WQLVC #HealthcareInnovation #DataDriven #GenAI #PatientCare #GlobalEnablement #DigitalTransformation #StrategyOne #LifeSciences #StrategySoftware #Pfizer

39